Survival of hemopoietic progenitors in the G0 period of the cell cycle does not require early hemopoietic regulators.
Although it is generally held that hemopoietic stem cells in steady-state marrow are dormant in the cell cycle, the direct proof for this concept has been lacking. In the present study, we have documented the development of human multipotential blast cell colonies from single cells by daily observation of the growth of candidate progenitors. The results clearly demonstrated that early hemopoietic progenitors may remain as single cells for more than 2 weeks of incubation. Once the progenitors began proliferation, the subsequent growth was characterized by steady cell doubling. Next, we tested the survival of blast cell colony progenitors in the presence of neutralizing antibodies prepared against early acting hemopoietic factors including interleukin (IL) 1 alpha, IL-1 beta, IL-3, IL-6, and granulocyte colony-stimulating factor. Cultures were initiated with individual antibodies, and, on day 14, IL-3 and the corresponding growth factor in concentrations that neutralize the antibodies were added. On days 18-27 of culture, blast cell colonies containing 25 or more cells were identified and replated for analysis of their ability to form secondary colonies. The cumulative frequency of the blast cell colonies in cultures containing antibody did not differ significantly from that of the control group containing rabbit IgG. A combination of anti-IL-1 alpha, anti-IL-1 beta, anti-IL-6, and anti-granulocyte colony-stimulating factor did not affect the survival of dormant blast cell colony-forming cells. These results indicate that survival of hemopoietic stem cells in the G0 period of the cell cycle is independent of early hemopoietic regulators.
Leary
A G
AG
Veteran's Administration Medical Center, Charleston, SC 29403.
Hirai
Y
Y
Kishimoto
T
T
Clark
S C
SC
Ogawa
M
M
D000328:Adult; D000906:Antibodies; D001854:Bone Marrow Cells; D002453:Cell Cycle; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D002999:Clone Cells; D003115:Colony-Stimulating Factors / Q000494:pharmacology*; D016179:Granulocyte Colony-Stimulating Factor; D006412:Hematopoietic Stem Cells / Q000166:cytology* / Q000187:drug effects; D006801:Humans; D007377:Interleukin-3 / Q000276:immunology / Q000494:pharmacology*; D015850:Interleukin-6; D007378:Interleukins / Q000276:immunology / Q000494:pharmacology*; D007399:Interphase
D000906:Antibodies; D003115:Colony-Stimulating Factors; D007377:Interleukin-3; D015850:Interleukin-6; D007378:Interleukins; D016179:Granulocyte Colony-Stimulating Factor